Skip to content
Medical Health Aged Care

SARI – Sarcoidosis Advocacy and Research Initiative at UNSW Sydney

UNSW Sydney 2 mins read

Sarcoidosis is a little-known condition that may attack virtually every organ in the body, is very difficult to diagnose and for which there are very few treatments, and certainly no cure. The incidence and prevalence in Australia is unknown, but is probably 20-30/100,000 representing between 5-8,000 patients nationally.

Sarcoidosis may present acutely, with a sudden and severe onset, or may have a slow, insidious presentation. Disease duration and severity vary. Some patients may have a relatively short disease duration of several months to a year or two, with the disease then going into remission, either spontaneously or with the help of medication. Other patients may develop a chronic form of sarcoidosis in which the disease remains active for many years. Progression of the disease over time may lead to increasing morbidity, often lung and heart transplants or death.

Yet we know very little about this disease, diagnosis is difficult, management is haphazard and there is no cure. The National Health and Medical Research Council (NHMRC) has never funded a research project on sarcoidosis and since 2007, when sarcoidosis was the focus of an editorial in the Australian Medical Journal, virtually no research has been undertaken in Australia. There is no registry of sarcoidosis patients in Australia, but in NSW alone over 1100 cases patients with a primary diagnosis of sarcoidosis presented to the Emergency Department (ED) over a five year period.

SARI is a new multi-disciplinary initiative at UNSW to advocate on behalf of all Australian sarcoidosis patients for greater recognition of this condition and greater support for research on improved methods of diagnosis, management and cure. This is important not only for those suffering from sarcoidosis but also for a better understanding of a range of related auto-immune conditions which appear to be on the increase.

SARI is seeking funds from the public and Government to begin research on new novel diagnostic methods and better treatment regimes, as well as a better understanding of immune system responses and genetic predisposition to suffering from sarcoidosis.

SARI will be launched by the Deputy Vice Chancellor, Research and Enterprise, Prof. Nicholas Fisk, at 1:00pm on Thursday 26th October in the Peter Farrell room in the Scientia Building at the UNSW Kensington Campus (Entrance via Botany St).

For further information contact SARI Secretary Prof. Branko Celler 0418 228 297



Contact details:

SARI Secretary Prof. Branko Celler (0418 228 297)

More from this category

  • CharitiesAidWelfare, Medical Health Aged Care
  • 01/03/2024
  • 06:01
Leukaemia Foundation

Leukaemia Foundation calls for greater awareness of myeloma as incidence rates set to more than double by 2035?

With myeloma incidence rates set to more than double by 2035, the Leukaemia Foundation is urgently calling for greater awareness and equitable access to treatment across the country, so myeloma patients have the best chance of survival, no matter where they live. As Myeloma Awareness Month launches today, Leukaemia Foundation CEO Chris Tanti said while survival rates for some blood cancers are improving, those diagnosed with myeloma still face a 50/50 chance of survival. “As many as 4 in 5 Australians are not confident in recognising the main symptoms of a blood cancer, like myeloma, leaving them at risk of…

  • Medical Health Aged Care
  • 01/03/2024
  • 06:00
Issued by Cube on behalf of Arthritis Australia

Arthritis Australia welcomes cheaper arthritis medicines

MEDIA RELEASE: 1st March 2024 More medicines now eligible for 60 day dispensing from March 1 2024 [Sydney, Australia] Arthritis Australia has welcomed access to cheaper medicines commonly used to treat arthritis, with the rollout of a new tranche of medicines eligible for 60 day dispensing from March 1 2024. Doctors will be able to write a 12-month script for medicines commonly used for arthritis conditions, including prednisolone, methotrexate DBL, Leflunomideand Ciclosporin, allowing a two-month supply to be dispensed when patients visit their pharmacy. Arthritis Australia CEO Jonathan Smithers said “Many people living with arthritis who are struggling with the…

  • Medical Health Aged Care
  • 29/02/2024
  • 11:48
Dementia Australia

ONE WEEK TO GO until Cronulla’s Memory Walk & Jog!

With only a few sleeps to go walkers, joggers and runners are gearing up to participate in the 2024 Cronulla Memory Walk & Jog. More than 500 people have already signed-up to take part – but there’s always room for more with online registrations still open, or sign-up on the day of the event. Dementia Australia CEO Maree McCabe AM said it is fantastic to see locals from Cronulla communities throwing their support behind Memory Walk & Jog. “As we prepare to host Memory Walk & Jog on Sunday 10 March at Don Lucas Reserve for another successful year, we…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.